About

Our Vision

Saving vision through
groundbreaking
technologies

We have built a company dedicated to preserving the ability to see. OculoTherapy was formed from the vision of Dr. Monica Jablonski at the Hamilton Eye Institute, University of Tennessee Health Science Center. Her laboratory is instrumental in the innovation of products for the treatment of glaucoma as well as other major eye diseases.

Our genetic-based research revealed for the first time, certain key control points (calcium channels) in the human eye necessary for maintaining several aspects of normal, heathy vision.

Our Vision

Saving vision through
groundbreaking
technologies

We have built a company dedicated to preserving the ability to see. OculoTherapy was formed from the vision of Dr. Monica Jablonski at the Hamilton Eye Institute, University of Tennessee Health Science Center. Her laboratory is instrumental in the innovation of products for the treatment of glaucoma as well as other major eye diseases.

Our genetic-based research revealed for the first time, certain key control points (calcium channels) in the human eye necessary for maintaining several aspects of normal, heathy vision.

A distinctly improved treatment for glaucoma.

A first-of-a-kind treatment for neurodegenerative disorders of the eye including atrophic age-related macular degeneration (AMD).

Our passion for innovation of products for the treatment of
glaucoma and other eye diseases has led to the development of
new therapeutics.

Extended-release formulations/delivery systems for these drug treatments that enhances efficacy as well as patient compliance.

Our passion for innovation of products for the treatment glaucoma and other eye diseases has led to development of new therapeutics that include.

A distinctly improved treatment for glaucoma.

Extended-release formulations/delivery systems for these drug treatments that enhances efficacy as well as patient compliance.

A first-of-a-kind treatment for neurodegenerative disorders of the eye including atrophic age-related macular degeneration (AMD).

Our passion for innovation of products for the treatment of
glaucoma and other eye diseases has led to the development of
new therapeutics.

These new solutions to long-standing limitations of current medications will support our goal of offering protection against vision loss to over

3 million glaucoma sufferers in the US

and nearly 100 million, worldwide;

and to the 11 million in the US and 170 million worldwide, who suffer from atrophic AMD.

We have built a company dedicated to preserving the ability to see. OculoTherapy was formed from the vision of Dr. Monica Jablonski at the Hamilton Eye Institute, University of Tennessee Health Science Center. Her laboratory is instrumental in the innovation of products for the treatment of glaucoma as well as other major eye diseases.

Learn More